.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

ePoster
P102

Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study

Termin

Datum: 05.12.

Zeit: 11:50 – 11:55

Redezeit: 3 Min.

Diskussionszeit: 2 Min.

Ort / Stream:

ePoster station 1

Poster

Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study

Session

ePoster 01

Thema

CGRP (receptor) inhibitors in the clinic